Fed. Circ. Upholds Preliminary Injunction On Biaxin XL

Law360, New York (October 21, 2008, 12:00 AM EDT) -- Echoing its earlier decision upholding a preliminary injunction in a suit over patents for Abbott Laboratories' antibacterial drug Biaxin XL, a federal appeals court ruled Tuesday that Sandoz Inc. could not start marketing its generic version before the resolution of the patent trial between the two companies.

The U.S. Court of Appeals for the Federal Circuit's decision to let stand the April 2007 preliminary injunction granted by the U.S. District Court for the Northern District of Illinois relied on the Federal Circuit's January 2007 decision against...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.